|Day Low/High||1,444.38 / 1,509.81|
|52 Wk Low/High||211.00 / 1,794.99|
Liquidity, FOMO and a short squeeze are driving market action.
* It's the mother of all short squeezes (part deux) * Does he live under water? "Yeah, like Bizarro Superman, Superman's exact opposite, who lives in the backwards Bizarro world. Up is down, down is up, he says hello when he leaves, goodbye when he...
In less than an hour we will end the week, which also shuts the book on July - are we really one-third of the way through the current quarter already? Despite the mixed performance this week that saw the Dow trade off modestly, the S&P 500 inch hig...
Huge earnings news and economic reports will drive the indices while aggressive speculative trading continues in smaller stocks.
Morgan Stanley analyst Adam Jonas raises Tesla's price target to $1,050 from $740 with a bull case target of $2,500. Also, Piper Sandler upgrades Kraft Heinz to overweight with a price target of $39.
Selling is broadening and speculative trading is narrowing, but it's tough to read too much into either yet.
In a 'normal' recession, these would be real losers -- but right now? They look like numero 'UNO'.
And there is a particular Brazilian ETF that is worth exploring if you want to take advantage of rising commodity prices and the falling U.S. dollar.
Precious metals reverse on a strong dollar, which should trigger some rotational action.
Hyliion via SHLL appears to be the more attractive risk versus reward.
Some form of fiscal compromise is widely expected, but I see three risks.
Monetary policy, fiscal policy, and major earnings news are all on the docket.
What has changed significantly has been the value of the U.S. dollar relative to peer currencies.
Will next week bring a resumption in technology leadership, further rotation, or broader selling?
It's probably time to start paying more attention to Nikola. And watch Tortoise Acquisition and Spartan Energy.
I'm doing some dip buying amid weakness in large-cap tech stocks.
CRBP has topline Phase 3 data for its primary compound Lenabasum for Systemic Sclerosis due out this summer.
* Will the Embassy tit for tat be the nail in the market (that many haven't been looking at) and be the catalyst for the market's relentless advance from March to end? * Yesterday's outside day may have been a dark moment in time for the markets and...
FATMAANN names are leading to the downside, but small-caps and value are outperforming.
Plus, why shares of vaccine maker Moderna are taking a hit.
Typically, when leading names correct, the entire market will fall in tandem, but here's what's happening this time.
Investors might have to take it on the chin -- and then do some soul searching -- as names like Microsoft, Tesla and other stars get hit.
There are opportunities but you better be selective and move fast.
Microsoft is awesome and so is their CEO, and I have serious thoughts on Tesla.
* In pre-market trading at $1642 * I have been waiting patiently to short Tesla for years * Tesla goes on my Best Ideas List (short) Tesla is no longer a hard to borrow (short) - so, in accordance with my core shorting tenet (of avoiding high short ...
Earnings reports continue to outperform, but can this support equity markets at these levels now?